Clinical Trials Logo

PTCL clinical trials

View clinical trials related to PTCL.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05238064 Not yet recruiting - PTCL Clinical Trials

Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL

Start date: March 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The study is to investigate the safety, tolerability and efficacy of PI3Kδ inhibitor Parsaclisib in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in frontline treatment of patients with peripheral T-cell lymphoma (PTCL).

NCT ID: NCT04705090 Not yet recruiting - PTCL Clinical Trials

A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

Start date: April 2021
Phase: Phase 2
Study type: Interventional

A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T/NK cell lymphoma.